<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255604</url>
  </required_header>
  <id_info>
    <org_study_id>ILIT</org_study_id>
    <nct_id>NCT02255604</nct_id>
  </id_info>
  <brief_title>Effect of Intralymphatic Immunotherapy</brief_title>
  <official_title>Effect of Intralymphatic Immunotherapy at Basophil Response and Plasmacell Kinetic in Patients With Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to investigate whether specific immunotherapy can be delivered&#xD;
      directly into a lymph node. The investigators think that a direct introduction of allergen to&#xD;
      the antigen presenting cells in the lymph node a give a strong immune response and that this&#xD;
      can change the number of injections needed in allergen immunotherapy. The investigators do&#xD;
      measurements of clinical effect and a variety of paraclinical test to see if the&#xD;
      investigators can find af biomarker of successful specific immune therapy of grass allergy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are injected with 3 or 4 doses of alk 225 Phleum Pratense 1000 standard quantity&#xD;
      units/ml in a lymph node in the groin.&#xD;
&#xD;
      The investigators monitor clinical response and use of medication during the grass pollen&#xD;
      season. SMS (Symptom and Medication Score) will be used.&#xD;
&#xD;
      The investigators count the number of immunoglobulin E grass producing plasma cells in blood&#xD;
      one week after each injection. The investigators also do basophil activation tests, nasal&#xD;
      provocation tests and titrated skin prick test to monitor effect.&#xD;
&#xD;
      Adverse events will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 1, 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cSMS (Combined Symptom and Medication Score)</measure>
    <time_frame>3 years</time_frame>
    <description>cSMS, Combined symptom and medication score, during grass pollen season in three years follow up.&#xD;
Minimal score 0, Maximal score 18. Higher score means worse outcome.&#xD;
Scale:&#xD;
Itchy/red eys: 0-3, Runny eyes: 0-3, Itchy nose: 0-3, Runny nose: 0-3, Block nose: 0-3, Sneezes: 0-3. Topical antihistamine 1.5 points/1 point. Nasal corticosteroid: 1 point/2 points. Oral antihistamine: 6 points/1 point. Oral prednisolon 1.5 point /3 points.&#xD;
Elements are summed to a combined score. Different combination methods exists. EAACI recommends means, i.e. symptoms 0-3 plus medicationscore 0-3. This scoringsystem was applied in the last follow-up year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Grass Specific Immunoglobulin E Producing Plasmacells</measure>
    <time_frame>one week from vaccinations</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Basophil Sensitivity</measure>
    <time_frame>2 years</time_frame>
    <description>Flowcytometry based analysis of basophil cells reaction to allergen provocation.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Allergy</condition>
  <condition>Immune Tolerance</condition>
  <condition>Injection Site Discomfort</condition>
  <arm_group>
    <arm_group_label>intralymphatic immune therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 intralymphatic immune therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no intralymphatic immune therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.</intervention_name>
    <description>4</description>
    <arm_group_label>intralymphatic immune therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.</intervention_name>
    <description>3 injection into a lymphnode</description>
    <arm_group_label>3 intralymphatic immune therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 ml Isoton saline</intervention_name>
    <description>4 injection into a lymphnode</description>
    <arm_group_label>no intralymphatic immune therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Allergic rhinitis to grass pollen, more than 3 mm reaction at skin prick test for&#xD;
             grass, age between 18 and 40 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled asthma.&#xD;
&#xD;
          -  Severe asthma with post bronchodilator test forced expiratory volume at 1 second less&#xD;
             than 70% of expected.&#xD;
&#xD;
          -  Severe co morbidity. Allergy to Fenol or Aluminium hydroxid.&#xD;
&#xD;
          -  Any autoimmune diseases. Treatment with beta blocking medicine.&#xD;
&#xD;
          -  Any heart diseases.&#xD;
&#xD;
          -  Severe arterial hypertension. Kidney failure.&#xD;
&#xD;
          -  Known malignancy. Known pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SÃ¸ren Helbo SH Skaarup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lungemedicinsk forskningsafdeling. Aarhus University Hospital.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lungemedicinsk Forskningsafdeling. Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <results_first_submitted>November 10, 2020</results_first_submitted>
  <results_first_submitted_qc>February 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2021</results_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Allergen immunotherapy</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015.&#xD;
Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 4</description>
        </group>
        <group group_id="P2">
          <title>3 Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection.&#xD;
alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 3 injection into a lymphnode</description>
        </group>
        <group group_id="P3">
          <title>no Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control.&#xD;
0.1 ml Isoton saline: 4 injection into a lymphnode</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015.&#xD;
Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 4</description>
        </group>
        <group group_id="B2">
          <title>3 Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection.&#xD;
alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 3 injection into a lymphnode</description>
        </group>
        <group group_id="B3">
          <title>no Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control.&#xD;
0.1 ml Isoton saline: 4 injection into a lymphnode</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.67" spread="5.52"/>
                    <measurement group_id="B2" value="29.92" spread="6.80"/>
                    <measurement group_id="B3" value="30.58" spread="7.43"/>
                    <measurement group_id="B4" value="30.72" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in cSMS (Combined Symptom and Medication Score)</title>
        <description>cSMS, Combined symptom and medication score, during grass pollen season in three years follow up.&#xD;
Minimal score 0, Maximal score 18. Higher score means worse outcome.&#xD;
Scale:&#xD;
Itchy/red eys: 0-3, Runny eyes: 0-3, Itchy nose: 0-3, Runny nose: 0-3, Block nose: 0-3, Sneezes: 0-3. Topical antihistamine 1.5 points/1 point. Nasal corticosteroid: 1 point/2 points. Oral antihistamine: 6 points/1 point. Oral prednisolon 1.5 point /3 points.&#xD;
Elements are summed to a combined score. Different combination methods exists. EAACI recommends means, i.e. symptoms 0-3 plus medicationscore 0-3. This scoringsystem was applied in the last follow-up year.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015.&#xD;
Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 4</description>
          </group>
          <group group_id="O2">
            <title>3 Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection.&#xD;
alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 3 injection into a lymphnode</description>
          </group>
          <group group_id="O3">
            <title>no Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control.&#xD;
0.1 ml Isoton saline: 4 injection into a lymphnode</description>
          </group>
        </group_list>
        <measure>
          <title>Change in cSMS (Combined Symptom and Medication Score)</title>
          <description>cSMS, Combined symptom and medication score, during grass pollen season in three years follow up.&#xD;
Minimal score 0, Maximal score 18. Higher score means worse outcome.&#xD;
Scale:&#xD;
Itchy/red eys: 0-3, Runny eyes: 0-3, Itchy nose: 0-3, Runny nose: 0-3, Block nose: 0-3, Sneezes: 0-3. Topical antihistamine 1.5 points/1 point. Nasal corticosteroid: 1 point/2 points. Oral antihistamine: 6 points/1 point. Oral prednisolon 1.5 point /3 points.&#xD;
Elements are summed to a combined score. Different combination methods exists. EAACI recommends means, i.e. symptoms 0-3 plus medicationscore 0-3. This scoringsystem was applied in the last follow-up year.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.8" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.5" upper_limit="3.0"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating Grass Specific Immunoglobulin E Producing Plasmacells</title>
        <time_frame>one week from vaccinations</time_frame>
        <population>Due to technical flow-cytometry problem could analysis of circulating grass specific immunoglobulin E producing plasma cells not be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015.&#xD;
Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 4</description>
          </group>
          <group group_id="O2">
            <title>3 Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection.&#xD;
alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 3 injection into a lymphnode</description>
          </group>
          <group group_id="O3">
            <title>no Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control.&#xD;
0.1 ml Isoton saline: 4 injection into a lymphnode</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Grass Specific Immunoglobulin E Producing Plasmacells</title>
          <population>Due to technical flow-cytometry problem could analysis of circulating grass specific immunoglobulin E producing plasma cells not be performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Basophil Sensitivity</title>
        <description>Flowcytometry based analysis of basophil cells reaction to allergen provocation.</description>
        <time_frame>2 years</time_frame>
        <population>Due to technical problems data was not recorded at all time points and results are missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015.&#xD;
Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 4</description>
          </group>
          <group group_id="O2">
            <title>3 Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection.&#xD;
alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 3 injection into a lymphnode</description>
          </group>
          <group group_id="O3">
            <title>no Intralymphatic Immune Therapy</title>
            <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control.&#xD;
0.1 ml Isoton saline: 4 injection into a lymphnode</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Basophil Sensitivity</title>
          <description>Flowcytometry based analysis of basophil cells reaction to allergen provocation.</description>
          <population>Due to technical problems data was not recorded at all time points and results are missing.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015.&#xD;
Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 4</description>
        </group>
        <group group_id="E2">
          <title>3 Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.&#xD;
Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection.&#xD;
alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.: 3 injection into a lymphnode</description>
        </group>
        <group group_id="E3">
          <title>no Intralymphatic Immune Therapy</title>
          <description>Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.&#xD;
Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control.&#xD;
0.1 ml Isoton saline: 4 injection into a lymphnode</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache, fatigue</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>anaphylaxis</sub_title>
                <description>anaphylaxis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local reaction</sub_title>
                <description>Local swelling, edema and rubor at injection point</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hans JÃ¼rgen Hoffmann</name_or_title>
      <organization>Aarhus Universitets Hospital</organization>
      <phone>7845000</phone>
      <email>Hans.Jurgen.Hoffmann@ki.au.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

